Q

QuantumLoopAI

AI receptionist for NHS primary care

Sales Development Representative

Full-Time
No salary listed
Entry
London, UK
In PersonFive days per week in the Canary Wharf office; company events across the UK several times per year.
Sales & Account ManagementSales Development Representative

About the job

Requirements
  • The role is open to recent graduates and candidates finishing their degree in 2025 or 2026, with any academic discipline accepted.
  • Applicants must be based in or willing to relocate to London and able to work from the Canary Wharf office five days a week.
  • Applicants must be confident speaking to people, able to hold conversations, listen properly, and communicate clearly.
  • Applicants must be competitive and motivated by measurable results.
  • Applicants must be resilient and able to handle regular rejection as part of the sales process.
  • Applicants must be curious about artificial intelligence, the National Health Service, and business growth.
  • Applicants must be disciplined, able to manage their own time, stay organised, and maintain a high level of activity independently.
Responsibilities
  • Identify potential customers and research them.
  • Reach out to potential customers by phone, email, and LinkedIn.
  • Have structured conversations with general practitioner practice managers and partners to understand their challenges and introduce the product.
  • Book product demonstrations.
  • Manage sales activity in a customer relationship management system.
  • Build a pipeline of opportunities.
  • Contribute to commercial strategy and gain exposure to how the startup grows.
  • Work directly on activities that impact company revenue.

About the company

EMMA by QuantumLoopAI is an AI receptionist designed for NHS primary care. It answers patient calls during GP surgery hours instantly, with no queue or hold music. EMMA handles both clinical and administrative inquiries, triages to the right outcome, and integrates with NHS tools like Accurx. It is used across hundreds of GP surgeries and PCNs, serving over 2 million NHS patients. This reduces call-handling costs (up to about 80%) and improves patient access and satisfaction, while easing pressure on reception staff. QuantumLoopAI emphasizes NHS clinical safety, DTAC certification, and alignment with NHS standards. The company’s goal is to make primary care more accessible, efficient, and sustainable by eliminating phone bottlenecks and letting reception teams focus on in-person patient care.

Company Size

51-200

Company Stage

N/A

Total Funding

N/A

Headquarters

London, United Kingdom

Founded

2023

Get referred to QuantumLoopAI

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • QuantumLoopAI said on March 23, 2026 it raised over £6 million and serves more than 2 million patients.
  • The company is listed on the Crown Commercial Service RM6200 framework, easing NHS procurement.
  • QuantumLoopAI says practices save 15 workdays weekly and go live within two to three weeks.

What critics are saying

  • BBC reported EMMA failed to understand a stroke patient; Armthorpe surgery decommissioned it by August 2026.
  • Healthwatch Rotherham accused EMMA of accent problems on August 19, 2026, inviting NHS scrutiny and complaints.
  • If NHS practices judge EMMA inaccessible, procurement freezes spread quickly and the company loses its only market.

What makes QuantumLoopAI unique

  • EMMA targets NHS GP surgeries, not generic contact centers, with telephony workflows built for primary care.
  • QuantumLoopAI claims DTAC approval, DSPT compliance, and live integrations with eConsult, Accurx, ANIMA, System Connect, Rapid Health.
  • The company says it answers hundreds of calls simultaneously and supports 17 languages across NHS settings.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Stock Options

Conference Attendance Budget

Professional Development Budget

Growth & Insights

Headcount

6 month growth

-13%

1 year growth

-11%

2 year growth

-9%